Health
Novavax Covid vaccine highly effective, but not against S.Africa variant – Yahoo News Australia
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, …
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.
Novavax said it began working…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business20 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News18 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Noosa News7 hours agoHelp to make recycling stick